Madrigal Pharmaceuticals Inc (MDGL) Stock Price, Quote & News

Company Profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Industry: Biotechnology

Sector: Healthcare

Phone: 267 824 2827

Website: www.madrigalpharma.com

Address:

Four Tower Bridge, Suite 200 200 Barr Harbor Drive, West Conshohocken, United States

Doozio Oct. 27 at 7:52 PM

$MDGL if no faatch 💣 then wen 🌙?

0 · Reply

Wallst45 Oct. 26 at 7:50 PM

$MDGL things getting close to a buyout for Madrigal after RNA buyout today

3 · Reply

sarkar20 Oct. 26 at 6:43 PM

$MDGL One more rumor from Betaville cane good today, Novartis buying Avidity which Betaville rumored in August. They rumoured MDGL buyout in last December (2024), stilll no news on MDGL though!!

1 · Reply

BioRich Oct. 25 at 5:10 AM

$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.

0 · Reply

LiquidThetaOptions Oct. 25 at 2:52 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $417.55 Contracts: $MDGL December 18, 2026 $420 Calls Scale in: $103.64- $126.67 Scale out: $161.21-$207.27 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

Wallst45 Oct. 24 at 1:58 PM

$MDGL BMY or GILD

1 · Reply

Wallst45 Oct. 23 at 7:09 PM

$MDGL yes easy buyout it’s coming in my opinion

1 · Reply

timfris Oct. 23 at 3:32 PM

$MDGL Viking CC talked about interest in MASH. What better company to buy than this?

1 · Reply

Whiskeyunderthebed Oct. 23 at 1:00 PM

$MDGL I didn't buy yesterday as this is still being pushed down before the call. I will enter today and tomorrow if needed.

0 · Reply

Wallst45 Oct. 22 at 6:30 PM

$MDGL buyout anytime now

0 · Reply

Madrigal Pharmaceuticals: Rezdiffra Commercialization Bodes Well For Continued Growth

Oct 22, 2025, 8:00 AM EDT - 5 days ago

Madrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025

Oct 21, 2025, 4:05 PM EDT - 6 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Oct 16, 2025, 6:18 PM EDT - 11 days ago

Madrigal Pharma CEO talks competition in the liver disease treatment space

Sep 30, 2025, 7:30 AM EDT - 27 days ago

Madrigal Pharmaceuticals: Rezdiffra's US And EU Rollout Remains Promising

Sep 8, 2025, 10:27 AM EDT - 7 weeks ago

Madrigal Pharmaceuticals, Inc. (MDGL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

Madrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 19, 2025, 4:05 PM EDT - 2 months ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Aug 15, 2025, 4:04 PM EDT - 2 months ago

Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further

Aug 11, 2025, 8:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 8, 2025, 6:15 PM EDT - 2 months ago

Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

Aug 5, 2025, 5:44 PM EDT - 2 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 2 months ago

Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates

Jul 31, 2025, 5:49 PM EDT - 3 months ago

Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term

Jul 30, 2025, 5:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

Jul 25, 2025, 8:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025

Jul 22, 2025, 8:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH

Jul 16, 2025, 8:00 AM EDT - 3 months ago

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

Jun 20, 2025, 7:35 AM EDT - 4 months ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Jun 20, 2025, 6:30 AM EDT - 4 months ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

May 17, 2025, 8:10 AM EDT - 5 months ago

In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals

May 10, 2025, 7:15 AM EDT - 6 months ago

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

May 6, 2025, 4:20 PM EDT - 6 months ago

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra

May 1, 2025, 1:01 PM EDT - 6 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 6 months ago

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

Apr 29, 2025, 8:00 AM EDT - 6 months ago

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress

Apr 18, 2025, 8:00 AM EDT - 6 months ago

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

Apr 16, 2025, 7:00 AM EDT - 6 months ago

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.

Mar 11, 2025, 8:00 AM EDT - 8 months ago

Madrigal Appoints Jacqualyn A. Fouse, Ph.D.

Feb 28, 2025, 2:29 PM EST - 8 months ago

Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade)

Feb 26, 2025, 6:33 PM EST - 8 months ago

Madrigal CEO on Q4 earnings beat, MASH drug market opportunity

Feb 26, 2025, 12:28 PM EST - 8 months ago

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Feb 26, 2025, 11:41 AM EST - 8 months ago

Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook

Feb 26, 2025, 11:05 AM EST - 8 months ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 8 months ago

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 26, 2025, 6:30 AM EST - 8 months ago

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Feb 21, 2025, 8:00 AM EST - 8 months ago

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Feb 12, 2025, 8:00 AM EST - 9 months ago

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Jan 29, 2025, 11:50 AM EST - 9 months ago

MoneyShow's Best Investment Ideas For 2025: Part 7

ARCC ASML HESM IMMR MARA TOST VLGEA

Jan 19, 2025, 9:30 AM EST - 10 months ago

Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH

Jan 13, 2025, 6:45 AM EST - 10 months ago

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Jan 9, 2025, 6:22 AM EST - 10 months ago

Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion

Jan 8, 2025, 11:13 AM EST - 10 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MRK PFE

Jan 3, 2025, 8:00 AM EST - 10 months ago

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 25, 2024, 8:29 AM EST - 1 year ago

Top 3 Health Care Stocks That May Dip This Month

BFLY CNMD

Nov 6, 2024, 8:00 AM EST - 1 year ago

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Nov 3, 2024, 9:00 AM EST - 1 year ago

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion

Oct 31, 2024, 2:50 PM EDT - 1 year ago

Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Doozio Oct. 27 at 7:52 PM

$MDGL if no faatch 💣 then wen 🌙?

0 · Reply

Wallst45 Oct. 26 at 7:50 PM

$MDGL things getting close to a buyout for Madrigal after RNA buyout today

3 · Reply

sarkar20 Oct. 26 at 6:43 PM

$MDGL One more rumor from Betaville cane good today, Novartis buying Avidity which Betaville rumored in August. They rumoured MDGL buyout in last December (2024), stilll no news on MDGL though!!

1 · Reply

BioRich Oct. 25 at 5:10 AM

0 · Reply

LiquidThetaOptions Oct. 25 at 2:52 AM

0 · Reply

Wallst45 Oct. 24 at 1:58 PM

$MDGL BMY or GILD

1 · Reply

Wallst45 Oct. 23 at 7:09 PM

$MDGL yes easy buyout it’s coming in my opinion

1 · Reply

timfris Oct. 23 at 3:32 PM

$MDGL Viking CC talked about interest in MASH. What better company to buy than this?

1 · Reply

Whiskeyunderthebed Oct. 23 at 1:00 PM

$MDGL I didn't buy yesterday as this is still being pushed down before the call. I will enter today and tomorrow if needed.

0 · Reply

Wallst45 Oct. 22 at 6:30 PM

$MDGL buyout anytime now

0 · Reply

Wallst45 Oct. 22 at 4:13 PM

$MDGL BTFD

0 · Reply

Whiskeyunderthebed Oct. 22 at 2:01 PM

$MDGL if this goes into the teens- it's a no brainer to pick up a few.

0 · Reply

Quantumup Oct. 21 at 8:31 PM

Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.

0 · Reply

All_just_a_game Oct. 21 at 5:32 PM

$MDGL 250M revenue this quarter makes it an official billion dollar blockbuster run rate… and just getting started….

0 · Reply

Wallst45 Oct. 21 at 3:50 PM

$MDGL why no ER announcement yet ?

0 · Reply

LiquidThetaOptions Oct. 21 at 12:51 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $438.90 Contracts: $MDGL December 18, 2026 $440 Calls Scale in: $102.26- $124.98 Scale out: $159.07-$204.52 Can Easily Capture: 60% ROI Blended DTE: 425 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

shopno Oct. 20 at 11:35 PM

$IOVA that's exactly right! Another factor comes in play is competition or drug superiority. For instance, $VRNA got a superior COPD drug, and got 600-700% growth at BO since FDA approval in Q2 2024. For $MDGL , price had been muted even with solid revenue growth as the firstever MASH drug due to upcoming competitions and the fact that it's not most effective drug. For $IOVA the decline from post FDA approval took some time, but take a look at $TNXP -- another very poorly managed stock -- infamous for FOREVER reverse splitting. I had been in TNXP only since last reverse-split, and sold positions as it went 1000% on HYPE. And then it LOST 70% value since FDA approval -- even BEFORE the drug is launched. Just because TNXP had another F-grade managements, many investors who got in after the FDA approval in August dumped due to fear of failure launch by a low caliber CEO.

2 · Reply

Wallst45 Oct. 20 at 6:33 PM

$MDGL should get bought out soon

1 · Reply

LiquidThetaOptions Oct. 18 at 3:54 PM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MDGL Current Share Price: $442.13 Contracts: $MDGL December 18, 2026 $450 Calls Scale in: $95.76- $117.04 Scale out: $148.96-$191.52 Can Easily Capture: 60% ROI Blended DTE: 427 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

MoneyGroupLLC Oct. 17 at 2:05 PM

Enter: $MDGL NOV 21 2025 $440 CALLS Buy in Price: $35.00 - $38.00 Take Profit: $76.65 Stop Bleeding: $30.80 ROI Potential: 119% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

AMP19 Oct. 17 at 9:33 AM

$MDGL blockbuster value. Easy double by next year.

0 · Reply

svertical1 Oct. 17 at 5:28 AM

$IBRX $MDGL What Rev build- looks like for Biotech with $9.7B valuation. IMMUNITYBIO Rev growth accelerate faster with one more indication (Lymphopenia, Lung, etc). Madrigal Pharm $9.7B

0 · Reply

Market Cap	9.36B
Revenue (ttm)	180.13M
Net Income (ttm)	-465.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-258.64%
Debt to Equity Ratio	0.17

Volume	261,700
Avg Vol	326,908
Day's Range	N/A - N/A
Shares Out	22.20M
Stochastic %K	20%
Beta	-1.02
Analysts	Strong Sell
Price Target	$501.38